LX1033: Phase II started

Lexicon disclosed in its 4Q11 earnings that it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily 500 and 1,000 mg LX1033 and thrice-daily 500 mg LX1033 for 28 days ...